THERAPY DOSSIER · th-35e9e64ddace

Evasin-3

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23250107 ↗2012Mixed findings

Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)Apolipoprotein E-deficientAcute treatment 5 min after cerebral ischaemia onset in the stroke model; chron…

Model: Carotid cast-induced atherosclerosis; transient left middle cerebral artery occlusion

Evasin-3 reduced neutrophilic inflammation in both models, with lower intraplaque neutrophil and matrix metalloproteinase-9 content and a weak increase in collagen in carotid atherosclerosis, and reduced brain neutrophil infiltration after stroke, but administration after ischaemia onset did not im…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…